Overview
Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
Status:
Completed
Completed
Trial end date:
2007-10-01
2007-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Purpose: The purpose of this clinical trial is to look at the chemotherapy combination of docetaxel and capecitabine in the treatment of newly diagnosed or locally advanced prostate cancer, and to determine if this treatment is an acceptable, effective and a safe treatment option. In addition, this clinical trial will evaluate how this treatment affects chemicals (enzymes), and other cancer related genetic changes in the tumor. Optional: This clinical trial will conduct extra imaging studies for research purposes including combined endorectal prostate magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRSI) and diffusion weighted imaging (DWI) to evaluate prostate cancer and response to study treatment.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer CenterTreatments:
Capecitabine
Docetaxel
Criteria
Patients must have newly diagnosed prostate cancer with at least one of the followingcriteria:
- Clinical Stage > T2
- PSA > 15 ng/ml
- Biopsy Gleason's sum > 8
- All patients must have a minimum PSA value of > 5 ng/ml.
- Patients may not have evidence of distant systemic metastasis.
- Patients may not undergo concurrent hormonal, biologic, or chemotherapy.
- Patients may not have prior unanticipated severe reaction to fluoropyrimidine therapy
or known hypersensitivity to 5-fluorouracil.
- Patients with a history of severe reaction to docetaxel or other drugs formulated with
polysorbate 80 will not be eligible.
- Patients may not have an underlying cardiac disease.